AKT1 and acute myeloid leukemia: Although several mechanisms of VEN resistance in AML have been identified, recent research has shown that heterogeneity in resistance mechanisms across patient populations exists also at the transcriptomic and cell signaling levels, specifically with activation of the PI3K-AKT-mTOR signaling axis and energy metabolism pathways.